Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.
Type:
Grant
Filed:
April 9, 2015
Date of Patent:
October 4, 2016
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Sanjaya Singh, Alisa K. Waterman, Erik Depla, Toon Laeremans, Diane Van Hoorick, Cedric Jozef Néotère Ververken
Abstract: The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.
Type:
Grant
Filed:
January 16, 2015
Date of Patent:
September 13, 2016
Assignee:
Immunomedics, Inc.
Inventors:
Chien-Hsing Chang, Michele J. Losman, David M. Goldenberg
Abstract: The present invention relates to an N-terminal amino acid-modified insulinotropic peptide having a high activity, and to a pharmaceutical composition comprising the same. The insulinotropic peptide derivatives according to the present invention exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs. Therefore, the insulinotropic peptide derivatives and the pharmaceutical composition comprising the same according to the present invention can be effectively provided for the treatment of the diseases.
Type:
Grant
Filed:
July 16, 2008
Date of Patent:
August 23, 2016
Assignee:
HANMI SCIENCE CO., LTD
Inventors:
Sung Youb Jung, Chang Ki Lim, Dae Hae Song, Sung Min Bae, Young Hoon Kim, Se Chang Kwon, Gwan Sun Lee
Abstract: Methods and compositions are provided for enhancing beige fat adipogenesis, and screening for agents having this activity An adipocyte progenitor cell is contacted with an effective dose of an antagonist of unliganded vitamin D receptor (VDR) activity. The contacting may be performed under adipogenic conditions.
Type:
Grant
Filed:
March 11, 2014
Date of Patent:
August 23, 2016
Assignee:
The Board of Trustees of the Leland Stanford Junior Unviversity
Abstract: Methods for administering pressure changes to a user for the treatment and prevention of diseases and conditions are disclosed herein. Methods of administering Cyclic Variations in Altitude Conditioning Sessions (CVAC Session(s)) for the treatment of steroidogenesis, steroid levels, and treatment of serum lipid levels are disclosed herein. Also disclosed herein are methods of administering CVAC Session(s) for the treatment of steroid levels and steroidogenesis associated with HIV infection.
Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Abstract: The invention is in the field of prevention and medical treatment of liver diseases, in particular non-alcoholic steatohepatitis (NASH). The invention provides means and methods for the treatment of hepatic inflammation, fibrosis and more in particular NASH. More in particular, the invention provides a composition capable of raising anti-oxLDL antibodies in vivo for use in the treatment of liver inflammation or fibrosis.
Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.
Type:
Grant
Filed:
January 3, 2013
Date of Patent:
July 12, 2016
Assignee:
Antibody and Receptor Therapeutics Co., Ltd.
Inventors:
Dong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim
Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
June 28, 2016
Assignee:
Sanofi
Inventors:
Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
Abstract: Featured are methods and compositions for treating, managing, preventing, or reducing injury to the kidney of a mammal (e.g., a human) caused by one or more iodinated radiocontrast media. The methods include administering an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds, which includes native human PACAP38, native human PACAP27, native human vasoactive intestinal peptide (VIP), their agonists, analogs, fragments, and derivatives, with activities toward one or more of the PACAP/VIP receptors, including all of their various isoforms. Also provided are pharmaceutical compositions of one or more PACAP-like compounds, either alone or in combination with one or more other prophylactic/therapeutic agents useful for treating, managing, or preventing injury to the kidney of a mammal (e.g., a human) undergoing treatment with one or more iodinated radiocontrast media.
Type:
Grant
Filed:
November 16, 2012
Date of Patent:
May 31, 2016
Assignee:
The Administrators of the Tulane Educational Fund
Inventors:
Vecihi Batuman, Jerome L. Maderdrut, Min Li, David H. Coy
Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
Type:
Grant
Filed:
November 4, 2013
Date of Patent:
May 3, 2016
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
Abstract: Agents, compositions, and medicaments that pertain to modulating the activity of muscle specific kinase receptor (MuSK) and methods and uses thereof to modulate MuSK activity are encompassed herein. Also encompassed are screening assays to identify modulators of MuSK activity. Agents identified using the screening assays described herein are envisioned for use as therapeutics, alone or in compositions or in medicaments, to alleviate or delay motor dysfunction in subjects afflicted with a disorder associated with nerve terminal loss or fragmentation, such as amyotrophic lateral sclerosis, sarcopenia, or anti-MuSK myasthenia gravis.
Abstract: Methods of treating heart failure, or decreasing blood pressure, comprising administering an NP at an appropriate dose, or in an amount sufficient to provide particular concentrations of NP, are provided.
Type:
Grant
Filed:
October 28, 2011
Date of Patent:
April 19, 2016
Assignee:
Capricor Therapeutics, INC.
Inventors:
Daron Evans, Hsiao Lieu, William P. Van Antwerp
Abstract: The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD).
Type:
Grant
Filed:
February 6, 2014
Date of Patent:
April 5, 2016
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits enzyme activity of EL and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
Type:
Grant
Filed:
June 17, 2014
Date of Patent:
March 22, 2016
Assignee:
PHILOGEN S.P.A.
Inventors:
Dario Neri, Hans Menssen, Andreas Menrad, Christoph Schliemann
Abstract: The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding domains for two different binding sites of LRP6 and compositions and methods of use thereof.
Type:
Grant
Filed:
May 5, 2011
Date of Patent:
March 22, 2016
Assignee:
NOVARTIS AG
Inventors:
Feng Cong, Seth Ettenberg, David Jenkins, Ming Lei, Andreas Loew, Karen Vincent, Li Zhou
Abstract: Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.
Type:
Grant
Filed:
October 18, 2013
Date of Patent:
March 15, 2016
Assignees:
The Hospital for Sick Children, Human Matrix Sciences, LLC
Abstract: Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed for modulating the immune system. The modulations include down-regulation, up-regulation and apoptosis.
Type:
Grant
Filed:
May 19, 2014
Date of Patent:
February 9, 2016
Assignee:
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
Abstract: The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided is a method for repairing or regenerating a damaged muscle tissue of a subject.
Type:
Grant
Filed:
June 18, 2012
Date of Patent:
February 2, 2016
Assignee:
President and Fellows of Harvard College
Inventors:
Lee L. Rubin, Amanda Gee, Amy J. Wagers